



Remodulin[®] (treprostinil) – First-time generic

- On February 28, 2019, Sandoz launched an [AB-rated](#) generic version of United Therapeutics' [Remodulin \(treprostinil\)](#) injection.
 - Sandoz has been granted 180-days of exclusivity.
- Remodulin is approved for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise and in patients with PAH requiring transition from [epoprostenol](#).
- Treprostinil is also available as a branded extended-release tablet ([Orenitram[®]](#)) and inhalation solution ([Tyvaso[®]](#)). Orenitram and Tyvaso are approved for the treatment of PAH.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.